Table 1. Details of study participants.
| Study no | Age | Gender | Resistance pattern | HIV status | Year Rx ended |
|---|---|---|---|---|---|
| 1 | 35 | F | MDR-TB | Positive | 2014 |
| 2 | 70 | F | RR-TB | Negative | 2018 |
| 3 | 47 | F | MDR-TB | Negative | 2015 |
| 4 | 33 | M | MDR-TB | Positive | 2016 |
| 5 | 62 | M | MDR-TB | Negative | 2011 |
| 6 | 52 | M | MDR-TB | Positive | 2017 |
| 7 | 35 | F | MDR-TB | Positive | 2017 |
| 8 | 43 | F | MDR-TB | Positive | 2010 |
| 9 | 30 | F | MDR-TB | Positive | 2013 |
| 10 | 40 | F | Rif mono-TB | Positive | 2015 |
| 11 | 30 | F | RR-TB | Positive | 2014 |
| 12 | 33 | M | MDR-TB | Positive | 2013 |
Abbreviations: Rx, treatment; MDR, multidrug resistant TB; TB, tuberculosis; RR-TB, rifampicin-resistant TB; Rif mono-TB, rifampicin-mono resistant TB.